AsianScientist (Oct. 3, 2016) – US pharmaceutical company AbbVie on Thursday (Sep. 29) opened a small molecule active pharmaceutical ingredient (API) facility, the first phase of its new S$400m Singapore manufacturing site. The facility will support the growth of AbbVie’s oncology and women’s health pipeline.
The new 120,000-square-meter site, located in the Tuas Biomedical Park, is AbbVie’s first manufacturing facility in Asia and will also include a biologics manufacturing facility that is expected to be fully operational by the end of 2018.
Speaking at the opening ceremony, Site Director Dr. Marc O’Donoghue said, “Singapore is recognized as a leader in the biopharmaceutical industry and AbbVie is excited to open its facility and begin operations. Singapore has a robust infrastructure, a highly educated and skilled workforce and provides a supportive environment for manufacturing.”
Combined, the API and biologics facilities will employ more than 250 new employees, including skilled positions across manufacturing, technical operations, administration, quality, information technology and supply chain.
AbbVie’s manufacturing network now includes 13 locations across the United States, Europe, Asia and Puerto Rico, as well as strategic partnerships with third-party manufacturers.
———
Source: AbbVie.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
